PetCaseFinder

Peer-reviewed veterinary case report

How nipradilol and timolol eye drops lower dog eye pressure

By Maehara, S et al.·Published in Veterinary ophthalmology·2004·Department of Veterinary Surgery, Japan·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Effects of topical nipradilol and timolol maleate on intraocular pressure, facility of outflow, arterial blood pressure and pulse rate in dogs.

Species:
dog

Plain-English summary

A group of 12 healthy dogs, including mongrels, beagles, and an Akita, received eye drops containing either nipradilol or timolol maleate for 28 days to see how they affected eye pressure. Both medications successfully lowered intraocular pressure (IOP), which is important for treating conditions like glaucoma. Nipradilol worked as well as timolol maleate but caused fewer side effects related to blood pressure and heart rate. This suggests that nipradilol could be a safer option for managing glaucoma in dogs.

People also search for: dog glaucoma treatment · nipradilol for dogs · timolol maleate side effects in dogs

Abstract

Nipradilol is an alpha(1), beta-blocker with milder side effects than other beta-blockers used in humans. In this study the effects of nipradilol were compared with those of timolol maleate in dogs. Twelve clinically normal dogs (nine mongrels, two beagles, and one Akita) were used. We applied 0.25% nipradilol or 0.5% timolol maleate drops for a period of 28 days. Intraocular pressure (IOP) was measured before and after administration on the 2nd, 4th, 7th, 14th, 21st and 28th day. Blood pressure, pulse rate and coefficient of aqueous outflow (C-value) were also measured before and after administration on the 7th, 14th, 21st and 28th day. Both nipradilol and timolol maleate significantly lowered IOP from the 2nd day to the end of the study period. Nipradilol lowered IOP to an equivalent degree to timolol maleate. There was no significant change in blood pressure and pulse rate throughout the study period with administration of nipradilol. C-value showed a significant rise from the 14th day with administration of nipradilol, while it did not show any significant change during the study period with administration of timolol maleate. The reduction of IOP by nipradilol was similar to that by an existing beta-adrenergic antagonist, timolol maleate, but nipradilol was associated with fewer systemic side effects in dogs. Nipradilol appears to be a useful drug for treatment of glaucoma in dogs.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/15091320/